Abstract:Recent breakthroughs in stem cell biology, especially the development of induced pluripotent stem cell technique, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Improved understanding of stem cell biology, in addition to better control of stem cell fate, is critical to realize this potential. Small molecules, targeting specific signaling pathways and/or mechanisms, have been shown to be useful chemical tools in manipulating cell fate, state and function. These small molecules are starting to play increasingly important roles in both elucidating the fundamental biology of stem cells and facilitating the development of therapeutic approaches toward regenerative medicine. Such approaches could involve cell replacement therapies using homogenous functional cells produced under chemically defined conditions in vitro and the development of small-molecule drugs that can stimulate patients’ endogenous cells to repair and regenerate. Here, we review recent progress in using small molecules to sustain pluripotency, or induce differentiation of embryonic stem cells. We also highlight small molecules that can replace transcription factors and/or enhance efficiency during somatic cell reprogramming. Recent breakthroughs in stem cell biology, especially the development of induced pluripotent stem cell technique, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Improved understanding of stem cell biology, in addition to better control of stem cell fate, is critical to realize this potential. Small molecules, targeting specific signaling pathways and/or mechanisms, have been shown to be useful chemical tools in manipulating cell fate, state and function. These small molecules are starting to play increasingly important roles in both elucidating the fundamental biology of stem cells and facilitating the development of therapeutic approaches toward regenerative medicine. Such approaches could involve cell replacement therapies using homogenous functional cells produced under chemically defined conditions in vitro and the development of small-molecule drugs that can stimulate patients’ endogenous cells to repair and regenerate. Here, we review recent progress in using small molecules to sustain pluripotency, or induce differentiation of embryonic stem cells. We also highlight small molecules that can replace transcription factors and/or enhance efficiency during somatic cell reprogramming. Having the ability to give rise to an entire functional organism. In mammals, the fertilized egg and early embryonic cells are totipotent. Totipotent cells not only have the potential to give rise to all the cell types of the body, but also the cell types of entire extraembryonic tissues. Having the potential to give rise to all of the cell types of the body, but not the cell types that make up the extraembryonic tissues such as the placenta. Embryonic stem cells derived from the inner cell mass of pre-implantation embryo are pluripotent. Pluripotent stem cells also include germline stem cells and derivatives, epiblast stem cells (EpiSCs) derived from the late epiblast layer of post-implantation embryos, and induced pluripotent stem (iPS) cells from somatic cells. Particularly, human embryonic stem cells (or mouse EpiSCs) can differentiate into trophoblast by BMP4 treatment. Whether it is a kind of artificial potential caused by in vitro conditions is still unknown. Having the ability to develop into different cell types within the same cell lineage. For example, hematopoietic stem cells that are multipotent can give rise to all the blood cell types. A pre-implantation embryo of about 150 cells produced by cleavage of the fertilized egg. The blastocyst is a hollow sphere made up of an outer layer of cells called trophoblast (forming the placenta eventually), a fluid-filled cavity, and a cluster of cells called inner cell mass. The cluster of cells attached to the wall of the blastocyst. These cells eventually give rise to all the organs and tissues of the whole organism, but do not give rise to the extraembryonic placenta tissues. The ICM cells are used to generate embryonic stem cells. The cell population in the post-implantation embryo that develops from the inner cell mass. The epiblast represents the final embryonic founder cells with the potential to give rise to all cell types of the adult body.

Inducing somatic cells into pluripotent stem cells is an important platform to study the mechanism of early embryonic development

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Advances in Reprogramming of Peripheral Blood Cells to Induced Pluripotent Stem Cells

Inducing Pluripotency in Somatic Cells: Historical Perspective and Recent Advances

Evolution of Induced Pluripotent Stem Cell Technology

Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications

Induced Pluripotent Stem Cells: Generation Strategy and Epigenetic Mystery Behind Reprogramming

Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells

Research progress in reprogramming induced pluripotent stem cells

Remodeling of Epigenetic Landscape During Induced Somatic Cell Reprogramming

Epigenetic regulation of somatic cell reprogramming

Mechanisms underlying the formation of induced pluripotent stem cells

Progress regarding induction of pluripotent stem cells

Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells

Reprogramming stem cells in regenerative medicine

Progress in the Reprogramming of Somatic Cells

Small Molecules That Modulate Embryonic Stem Cell Fate and Somatic Cell Reprogramming

Mechanism and Methods to Induce Pluripotency

Manipulating cell fate through reprogramming: approaches and applications

Induced pluripotent stem cells generated from reprogramming differentiated cells by defined factors]